Rapport Therapeutics (RAPP) Insider Trading & Ownership $14.61 +0.18 (+1.25%) Closing price 04:00 PM EasternExtended Trading$13.72 -0.89 (-6.09%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Rapport Therapeutics (NASDAQ:RAPP) Insider Buying and Selling ActivityNumber OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$161.25KNumber OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$238K Get RAPP Insider Trade Alerts Want to know when executives and insiders are buying or selling Rapport Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address RAPP Insider Buying and Selling by Quarter Rapport Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/15/2025David BredtInsiderSell8,500$14.00$119,000.00 7/15/2025David BredtInsiderSell8,500$14.00$119,000.00 3/12/2025Troy A IgnelziCFOBuy9,900$10.10$99,990.00 3/12/2025Wendy B YoungDirectorBuy6,000$10.21$61,260.00 (Data available from 1/1/2013 forward) RAPP Insider Trading Activity - Frequently Asked Questions Who is on Rapport Therapeutics' Insider Roster? The list of insiders at Rapport Therapeutics includes David Bredt, James Healy, Troy A Ignelzi, and Wendy B Young. Learn more on insiders at RAPP. Which Rapport Therapeutics insiders have been buying company stock? The following insiders have purchased RAPP shares in the last 24 months: James Healy ($1,079,664.64), Troy A Ignelzi ($99,990.00), and Wendy B Young ($61,260.00). How much insider buying is happening at Rapport Therapeutics? Insiders have purchased a total of 59,932 RAPP shares in the last 24 months for a total of $1,240,914.64 bought. Which Rapport Therapeutics insiders have been selling company stock? The following insider sold RAPP shares in the last 24 months: David Bredt ($238,000.00). How much insider selling is happening at Rapport Therapeutics? Insiders have sold a total of 17,000 Rapport Therapeutics shares in the last 24 months for a total of $238,000.00 sold. More Insider Trading Tools from MarketBeat Related Companies XENE Insider Trading AGIO Insider Trading BEAM Insider Trading ARWR Insider Trading TWST Insider Trading HRMY Insider Trading IDYA Insider Trading IRON Insider Trading CNTA Insider Trading VCEL Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:RAPP) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredInstant Cash (every 3rd Monday)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
